US Pharma MarketingFDA grants fast track designation for Lundbeck’s Lu AH69593
FDA grants fast track designation for Lundbeck’s Lu AH69593 is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Lundbeck has secured fast track designation from the US FDA for its investigational treatment, Lu AH69593, to treat narcolepsy.
Source: Pharmaceutical Technology